PTO/SB/21 (02-04) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number TRADEN Application Number 10/798,037 TRANSMITTAL Filing Date 03-11-2004 **FORM** First Named Inventor Robbins, Jeffrey Art Unit (to be used for all correspondence after initial filing) **Examiner Name** Attorney Docket Number CHM02-GN054 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance communication Fee Transmittal Form to Technology Center (TC) Drawing(s) Appeal Communication to Board Licensing-related Papers of Appeals and Interferences Fee Attached Appeal Communication to TC Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Terminal Disclaimer Extension of Time Request Identify below): RETURN POST CARD Request for Refund **Express Abandonment Request** CD, Number of CD(s) Information Disclosure Statement Remarks Certified Copy of Priority INCLUDING FORM PTO/SB/08B AND (+) 18 CITED REFERENCES Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm David A. Mancino, Reg. 39,289 Taft, Stattinius & Hollister LLP Individual name Signature Date 21 2004 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. Typed or printed name Sharon A. Shelton, Paralegal

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

05-21-2004

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Signature



## Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on:

May 21, 2004 Sharon A. Shelton

(Date) (Name)

(Signature)

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## Application of:

Applicant

Robbins, Jeffrey

Serial No.

10/798,037

Filed On

March 11, 2004

Title

CARDIAC-PREFERRED GENETIC ALTERATION OF

TRANSGENIC RABBITS

Docket No.

CHM02-GN054

Examiner

Art Unit

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313

Dear Sir:

## INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. § 1.97, the Examiner's attention is directed to the references listed on the attached Form PTO-SB-08B. A copy of each of the listed references is provided.

It is to be understood that the present disclosure of art is in no way intended to be a waiver of any arguments or defenses available to the Applicant under the rules of the U.S. Patent {w0180015.1}

Information Disclosure Statement CHM02-GN054
Page 2

and Trademark Office and the statutes of the United States. No fee is required. The Commissioner is hereby authorized to charge any additional fees that may be required by this paper, or to credit any overpayment to Deposit Account 503072.

Respectfully submitted,

David A. Mancino Reg. No. 39,289

030074
TAFT, STETTINIUS & HOLLISTER LLP
425 Walnut Street, Suite 1800
Cincinnati, OH 45202-3957
(513) 357-9331
mancino@taftlaw.com

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Un	der the Paperwork Red	uction A	ct of 4995, no persons ar	e required to respond to a collection	of information unless it contains a valid OMB control in Complete if Known	number.
Substitu	te for form 1449/P104	QEMA		Application Number	10/798,037	
INFORMATION DISCLOSURE				Filing Date	03-11-2004	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Robbins, Jeffrey	
				Art Unit		
(Use as many sheets as necessary)			iecessary)	Examiner Name		
Sheet	2	of	2	Attorney Docket Number	CHM02-GN054	

Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
		ALPERT et al; Molecular mechanics of mouse cardiac myosin isoforms; Am J Physiol Heart Circ Physiol 2002, 283: H1446-54; USA	
		SHAH et al; Adenovirus-Mediated Genetic Manipulation of the Myocardial B-Adrenergic; J Thoracic Cardiov Surgery 2000, 120: 581-585; USA	
		SCHWARTZBAUER et al; The Tumor Suppressor Gene PTEN Can Regulate; J Biol Chemistry 2001, 276: 35786-93; USA	
		WIGLE et al; Hypertrophic Cardiomyopathy; Circulation 1995, 92: 1680-1692; Canada	
		BRAUNWALD et al; Contemporary Evaluation and Managemen of Hypertrophic; Circulation 2002, 106: 1312-1316; USA and Switzerland	
		JAMES et al; Genetic Manipulation of the Rabbit Heart via Transgenesis; Circulation 2000, 101: 1715-1721	
		AF192306; Def: Oryctolagus cuniculus slow type myosin heavy chain gene, promoter and partial cds.	
		AF192305; Def: Oryctolagus cuniculus alpha myosin heavy chain gene, promoter and partial cds.	

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031

Und	ewhe Paperwork Red	uchon Ad	ct of 1995, no persons ar	U.S. Patent e required to respond to a collection	and Trademark Office; U.S. DEPARTMENT OF COMMERCE of information unless it contains a valid OMB control number.	
Substitute for for the state of				Complete if Known		
Cuboman	The same of the sa			Application Number	10/798,037	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	03-11-2004	
				First Named Inventor	Robbins, Jeffrey	
	<b>4</b> 4			Art Unit		
(Use as many sheets as necessary)			ecessary)	Examiner Name		
Sheet	1	of	2	Attorney Docket Number	CHM02-GN054	

NON PATENT LITERATURE DOCUMENTS					
Examiner Cite Initials* No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		KELLER et al; Genetics of familial cardiomyopathies and arrhythmias; Swiss Med Wkly, 2002, Jul 27; 132(29-20): 401-407; Switzerland			
		CHARRON et al; Cooperative Interaction between GATA-4 and GATA-6 Regulates; Mol Cell Biol 1999, 19: 4355-4356; Canada			
		PATEL et al; Simvastatin Induces Regression of Cardiac Hypertrophy and Fibrosis; Circulation 2001, 104: 317-324; USA			
		CHEN et al; Ventricular muscle-restricted targeting of the RXRa gene reveals; Development 1998, 125: 1943-1949; USA and Great Britain			
		MINAMINO et al; Inducible Gene Targeting in Postnatal Myocardium by Cardiac-Specific; Circ Res 2001, 88: 587-592; USA			
		SOHAL et al; Temporally Regulated and Tissue-Specific Gene Manipulations in the Adult; Circ Res 2001, 89: 20-25; USA and Canada			
		NAGUEH et al; Tissue Doppler Imaging Consistently Detects Myocardial Contraction; Circulation 2000, 102: 1346-1350; USA			
		JAMES et al; Transgenic Rabbits Expressing Mutant Essential Light Chain do not; J Mol Cell Cardiol 2002, 34: 873-882; USA			
		MARIAN et al; A transgenic rabbit model for human hypertrophic cardiomyopathy; J Clin Invest 1999, 104: 1683-1692; USA			
		HAHN et al; Ischemic Protection and Myofibrillar Cardiomyopathy; Circ Res 2002, 91: 741-748; USA			

Examiner	Date	,
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.